Renal cell carcinoma: An update for the practicing urologist
Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinica...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-01-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388215000363 |
| _version_ | 1818967268452728832 |
|---|---|
| author | Sumanta K. Pal Paulo Bergerot Robert A. Figlin |
| author_facet | Sumanta K. Pal Paulo Bergerot Robert A. Figlin |
| author_sort | Sumanta K. Pal |
| collection | DOAJ |
| description | Systemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinical trials that were either recently completed or ongoing. (1) Though observation remains a standard of care following resection of localized disease, multiple trials are underway to assess VEGF- and mTOR-directed therapies in this setting. (2) While the preponderance of retrospective data favors cytoreductive nephrectomy in the context of targeted agents, prospective data to support this approach is still forthcoming. (3) The first-line management of mRCC may change substantially with multiple studies exploring vaccines, immune checkpoint inhibitors, and novel targeted agents currently underway. In general, prospective studies that will report within the next several years will be critical in defining the role of adjuvant therapy and cytoreductive nephrectomy. Over the same span of time, the current treatment paradigm for first-line therapy may evolve. |
| first_indexed | 2024-12-20T13:46:06Z |
| format | Article |
| id | doaj.art-4dae09bed2714875b1788b25f9b28ca4 |
| institution | Directory Open Access Journal |
| issn | 2214-3882 |
| language | English |
| last_indexed | 2024-12-20T13:46:06Z |
| publishDate | 2015-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj.art-4dae09bed2714875b1788b25f9b28ca42022-12-21T19:38:39ZengElsevierAsian Journal of Urology2214-38822015-01-0121192510.1016/j.ajur.2015.04.012Renal cell carcinoma: An update for the practicing urologistSumanta K. Pal0Paulo Bergerot1Robert A. Figlin2Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USAHealth Department of Federal District (SES) – HRAN, Brasilia, BrazilDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USASystemic therapy for metastatic renal cell carcinoma (mRCC) has evolved drastically, with agents targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) now representing a standard of care. The present paper is to review the current status of relevant clinical trials that were either recently completed or ongoing. (1) Though observation remains a standard of care following resection of localized disease, multiple trials are underway to assess VEGF- and mTOR-directed therapies in this setting. (2) While the preponderance of retrospective data favors cytoreductive nephrectomy in the context of targeted agents, prospective data to support this approach is still forthcoming. (3) The first-line management of mRCC may change substantially with multiple studies exploring vaccines, immune checkpoint inhibitors, and novel targeted agents currently underway. In general, prospective studies that will report within the next several years will be critical in defining the role of adjuvant therapy and cytoreductive nephrectomy. Over the same span of time, the current treatment paradigm for first-line therapy may evolve.http://www.sciencedirect.com/science/article/pii/S2214388215000363Renal cell carcinomaSdjuvant therapyCytoreductive nephrectomyVaccinesImmunotherapyPD-1Cabozantinib |
| spellingShingle | Sumanta K. Pal Paulo Bergerot Robert A. Figlin Renal cell carcinoma: An update for the practicing urologist Asian Journal of Urology Renal cell carcinoma Sdjuvant therapy Cytoreductive nephrectomy Vaccines Immunotherapy PD-1 Cabozantinib |
| title | Renal cell carcinoma: An update for the practicing urologist |
| title_full | Renal cell carcinoma: An update for the practicing urologist |
| title_fullStr | Renal cell carcinoma: An update for the practicing urologist |
| title_full_unstemmed | Renal cell carcinoma: An update for the practicing urologist |
| title_short | Renal cell carcinoma: An update for the practicing urologist |
| title_sort | renal cell carcinoma an update for the practicing urologist |
| topic | Renal cell carcinoma Sdjuvant therapy Cytoreductive nephrectomy Vaccines Immunotherapy PD-1 Cabozantinib |
| url | http://www.sciencedirect.com/science/article/pii/S2214388215000363 |
| work_keys_str_mv | AT sumantakpal renalcellcarcinomaanupdateforthepracticingurologist AT paulobergerot renalcellcarcinomaanupdateforthepracticingurologist AT robertafiglin renalcellcarcinomaanupdateforthepracticingurologist |